Comparative Pharmacology
Head-to-head clinical analysis: ANDROGEL versus H R 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROGEL versus H R 50.
ANDROGEL vs H.R.-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
12.5 mg orally twice daily
None Documented
None Documented
The terminal elimination half-life of testosterone from AndroGel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Category C
Category C
Androgen
Androgen